(Boursier.com) — Theradiag achieved revenue of 6.7 million euros compared to 6.3 million in the 1st half of 2022, an increase of +6.8%. Growth accelerated slightly during the second quarter of 2023 thanks to good commercial performances in Theradiag’s two business lines: +9.4% for Theranostics and +5.3% for In Vitro Diagnostics (IVD).
As of June 30, 2023, Theradiag’s net available cash amounted to 5.7 million euros, a level higher than the company’s plan, compared to 6.4 million euros as of December 31, 2022.
©2023 Boursier.com